Skip to main content
Article thumbnail
Location of Repository

Risk Assessment Based on FDG-PET Imaging in Patients with Synovial Sarcoma

By Jennifer W. Lisle, Janet F. Eary, Janet O’Sullivan and Ernest U. Conrad

Abstract

Synovial sarcoma generally is associated with poor prognosis. With recent advances in molecular biology, it has become apparent not all synovial sarcomas share the same tumor biology. 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) is useful for risk assessment in several types of sarcomas. We therefore assessed the clinical value of 18F-FDG-PET-derived maximum standard uptake value (SUVmax) for predicting survival in patients with synovial sarcoma. 18F-FDG-PET was performed in 44 patients with synovial sarcoma before therapy and resection. SUVmax was calculated for each tumor and then evaluated for prognostic usefulness along with metastasis at presentation, tumor grade, histopathologic subtype, age, gender, postsurgical margins, anatomic location, and tumor size for overall survival and progression-free survival. SUVmax ranged from 1.2 to 13.0 (median, 4.35). Pretherapy tumor SUVmax predicted overall survival and progression-free survival. Patients presenting with a SUVmax greater than 4.35 had a decreased disease-free survival and were therefore at high risk for having local recurrences and metastatic disease

Topics: Original Article
Publisher: Springer-Verlag
OAI identifier: oai:pubmedcentral.nih.gov:2674162
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles


    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.